Table 2. Description of scenarios for the economic evaluation of rotavirus vaccination, Kazakhstan.

Scenario	Vaccine parameters					Children <5 y of age, calibration to 2009 sentinel data
	Mean duration of protection, mo	Coverage	Efficacy against severe RVGE	Efficacy against mild RVGE		Deaths	Hospital admissions	Outpatient clinic visits*	Homecare episodes*
Base case	12	0.9	0.80	0.58		68	4,007	Is-0.2Ih	Im
Base case, low	12	0.9	0.74	0.51		63	3,740	0.6	0.5Im
Base case, high	12	0.9	0.86	0.64		74	4,274	1.4	1.5Im
Scenario A	12	0.89	0.80	0.58		68	4,007	Is-0.2Ih	Im
Scenario A, low	12	0.89	0.74	0.51		63	3,740	0.6	0.5Im
Scenario A, high	12	0.89	0.86	0.64		74	4,274	1.4(	1.5Im
Scenario B	12	1.0	0.80	0.58		68	4,007	Is-0.2Ih	Im
Scenario B, low	12	1.0	0.74	0.51		63	3,740	0.6	0.5Im
Scenario B, high	12	1.0	0.86	0.64		74	4,274	1.4	1.5Im
Scenario C	24	0.9	0.80	0.58		68	4,007	Is-0.2Ih	Im
Scenario C, low	24	0.9	0.74	0.51		63	3,740	0.6	0.5Im
Scenario C, high	24	0.9	0.86	0.64		74	4,274	1.4	1.5Im

*RVGE, rotavirus gastroenteritis; I_s, modeled incidence of severe RVGE; I_h, modeled incidence of hospital admissions; I_m, modeled incidence of mild RVGE.
†The numbers of outpatient clinic and homecare visits were not calibrated.